Medtronic Settles False Medicaid Claims for $2.8M

Medtronic Inc. has agreed to pay $2.8 million to settle allegations that the company knowingly submitted or caused the submission of false claims to state Medicaid programs for replacement insulin infusion pumps, the Pennsylvania Attorney General’s office announced earlier this week.

Allegedly, Medtronic—doing business as Medtronic Diabetes—improperly solicited Medicaid recipients to replace their insulin infusion pumps, in violation of a federal Anti-Solicitation Rule and similar state laws, leading to false claims filed to state health care programs such as Medicaid.

The lawsuit was originally filed by former Medtronic employees under the whistleblower provision of the False Claims Act.  The Act allows private parties with knowledge of fraud against the government to sue on behalf of the government and share in the recovery.  The whistleblowers’ portion of the settlement has yet to be announced.

The Chanler Group, in association with the Hirst Law Group, represents whistleblowers who take action under the False Claims Act to report fraud committed against the federal and state governments.  We have years of experience representing whistleblower clients who expose every kind of fraud against the government, including health care fraud, contract fraud, and tax fraud.  Read more about our expertise in False Claims Act cases and how you can take action.